Navigation Links
Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinson's Drug Development
Date:2/9/2010

NEW YORK, Feb. 9 /PRNewswire-USNewswire/ -- As part of its mission to do whatever it takes to speed development of life-transforming treatments and a cure for Parkinson's disease, The Michael J. Fox Foundation announced $1 million in total funding for seven research projects aiming to push forward critical research tools and new technologies to accelerate PD therapeutic development.

While new genetic and cellular targets have invigorated Parkinson's research over the past decade, converting these discoveries into practical treatments requires deliberate and strategic investment in the development of new research technologies and tools. This pursuit is critical to attaining the Foundation's ultimate goal: transformative new treatments that will make a tangible impact on patients' lives.

Five funded teams are working to develop improved pre-clinical disease models of PD that accurately mimic the pathology and symptoms of Parkinson's as it arises and progresses in humans. These models are critical not only for testing potential new Parkinson's treatments, but also for opening new therapeutic avenues to address particular clinical features of the disease.

Jim Greene, MD, PhD, of Emory University has been funded by MJFF since 2006 to develop an accurate model of gastrointestinal (GI) dysfunction, such as nausea, bloating and constipation, in Parkinson's. These symptoms of PD are poorly understood, and there is a dearth of treatment options to address them, in part because researchers lack a model that could be used to test new therapies. Dr. Greene is heading a collaboration between neurologists and GI specialists to examine the 'enteric nervous system' (ENS) -- a nervous system located in the stomach and intestines that contains, in both humans and pre-clinical models, nearly as many nerve cells as the brain. With follow-on funding from MJFF, the researchers are now building on Dr. Greene's exciting earlier results and examining the ENS in parkinsonian rodents to determine which nerve cells are damaged and thus responsible for causing the GI symptoms -- information that will dramatically speed efforts to develop therapeutic targets for new GI treatments.

Chenjian Li, PhD, of Weill Cornell Medical College was previously funded by MJFF to create the first rodent models of Parkinson's showing progressive degeneration of dopamine neurons, as is seen in the human condition. His team successfully used bacterial artificial chromosome (BAC) technology to generate rat lines with five of the most common genetic mutations associated with PD (three alpha-synuclein lines and two LRRK2 lines).  Now J. Timothy Greenamyre, MD, PhD, of the University of Pittsburgh is collaborating with Dr. Li to characterize the alpha-synuclein models' neurobehavioral deficits, neurochemical alterations, dopaminergic cell loss, neuropathology and molecular features. If successful, the project could lead, for the first time, to models of PD that faithfully recapitulate various components of the human disease and, optimally, help speed the development of new treatments.

The sixth funded team, led by Albert Leentjens, MD, PhD, of Maastricht University Hospital in the Netherlands, is working to validate clinical scales that would allow doctors to accurately measure anxiety disorders in PD. Dr. Leentjens will lead an international, six-center study assessing 360 Parkinson's patients for anxiety symptoms through a structured interview and completion of the most common anxiety rating scales. Information on disease variables, motor function, mood, and cognition will be collected. This is the largest study on anxiety disorders in Parkinson's disease to date, and will result in the first validated description of both established and atypical anxiety syndromes in PD as well as validation of the rating scales used to measure them -- a prerequisite for the design of effective clinical studies of anxiety in PD and new treatments to alleviate this troubling symptom.

The full list of funded projects, made possible through the generous support of The Brin Wojcicki Foundation, is below. As with all MJFF awards, continued funding is dependent on the achievement of specific, pre-determined milestones. Grant abstracts and researcher biosketches for all funded awards are available through the Searchable Database of Funded Grants on the Foundation's Web site, www.michaeljfox.org.

Gastrointestinal Function in Parkinson's Rodents

James Greene, MD, PhD, Emory University

Analysis of the Role of PPN Neurons in Postural Disturbances in a Non-human Primate Model of Parkinson's Disease

Chantal Francois, PhD, Hopital de la Salpetriere

Characterization of E46K and A53T Alpha-Synuclein BAC Transgenic Rats

J. Timothy Greenamyre, MD, PhD, University of Pittsburgh

A Non-human Primate Alpha-Synuclein Model of Parkinson's Disease

Jeffrey Kordower, PhD, Rush University Medical Center

The Validation of Anxiety Scales in Parkinson's Disease

Albert Leentjens, MD, PhD, Maastricht University Hospital

Artificial Chromosome Transgenic Mice as Model for Progressive Parkinson's Disease

Robert Nussbaum, MD, University of California, San Francisco

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. MJFF has funded over $171 in research to date. 

SOURCE Michael J. Fox Foundation

RELATED LINKS
http://www.michaeljfox.org

'/>"/>

SOURCE Michael J. Fox Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Would You Like to Own a Thriller Album Autographed by Michael Jackson Himself?
2. Aton Pharma Announces Michael H. Richardson to Head Orphan Drug Division
3. Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinsons Disease Biomarker Pipeline
4. Aleres Dr. Michael Taitel Presents Compelling Evidence at IBI/NBCH Health & Productivity Forum that Wellness Programs Positively Impact Health & Productivity
5. Michael Jackson Propofol Expert, Barry Friedberg MD, Spoke at Pan Pacific Surgery Meeting
6. TV Wellness Expert Jillian Michaels Teams With Harley-Davidson to Help Women Channel Their Inner Drive and Live More Fulfilling Lives
7. Michael J. Fox Foundation Awards $2 Million for Clinical Research on Postural Instability and Gait Disturbances in Parkinsons Disease
8. Michael J. Fox Foundation Awards $1 Million for Critical Step Toward Development of Dyskinesia Treatments
9. Rush Limbaugh & Michael Steele Join Tea Party Support & Social Security Institute-Demand GOP Senate Stop ObamaCare by Any Means Possible
10. Dr. Michael Aziz Releases a New Nutrition Book That Debunks Most Popular Diets and Diet Books
11. BIDMC scientists awarded grants from Michael J. Fox Foundation for Parkinsons research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Worth, TX (PRWEB) , ... October 13, 2017 ... ... financial planning agency serving communities in the greater Dallas, Miami, and Raleigh regions, ... young boy fighting to overcome a rare and deadly chromosome abnormality. , After ...
(Date:10/13/2017)... IL (PRWEB) , ... October 13, 2017 , ... ... which established the certification process to promote standards of excellence for the field ... Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at the ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Texas , Oct. 11, 2017  True ... services, has amplified its effort during National Breast ... about hereditary cancer risks. ... of Clinical Oncology calculated that more than 10 ... have inherited mutations in BRCA1 or BRCA2 and have ...
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical Services, ... solutions for injectable drug administration, today shared the results ... Adapter for improving the intradermal administration of polio vaccines. ... Vaccination Summit in May 2017 by Dr. Ondrej ... Department, World Health Organization (WHO), and recently published in ...
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
Breaking Medicine Technology: